Aims
-
Identify novel environmental and biological markers for cancer risk assessment.
-
Improve detection of pre-malignant and early-stage disease.
-
Advance cancer interception through development of interventions in pre-malignant and early-stage disease.
The Cancer Risk, Detection, and Interception Program focuses on identifying cancer at its earliest stages and intervening before the disease becomes difficult to treat. Experts in epidemiology, biology, genetics, environmental health, and clinical science work together to understand how cancers begin and how early changes—whether environmental, genetic, or cellular—can be detected and acted upon. This work supports the development of improved risk‑assessment tools, targeted screening approaches, and technologies that enhance early detection of pre‑malignant and early‑stage disease.
Beyond identifying risk and advancing detection, the program develops interventions that disrupt cancer development in individuals with pre‑cancerous lesions or early, localized tumors. Researchers investigate biological pathways involved in early tumor formation and evaluate therapeutic strategies with potential for early interception. These efforts position CRDI to bridge discovery science with clinical readiness, offering approaches that can halt cancer progression long before advanced treatment is necessary.
